Tag: Parkinson’s disease
FDA approval of Exablate Neuro for the treatment of tremor-dominant Parkinson’s...
InSightec has announced that The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) has approved an expansion...
Deep brain stimulation associated with a decreased risk of fall in...
Chronic subthalamic deep brain stimulation (DBS) is associated with a decreased risk for recurrent falls and delays the onset of psychosis in patients with...
Vercise deep brain stimulation system gains FDA approval
The US Food and Drug Administration (FDA) has approved the Vercise deep brain stimulation (DBS) system (Boston Scientific). DBS is used to treat the symptoms...
FDA approves pivotal study of Exablate Neuro for treatment of Parkinson’s...
INSIGHTEC has received approval from the US Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia...
Aleva Neurotherapeutics raises US$13 million in latest financing round
Aleva Neurotherapeutics has raised US$13 million in a Series D financing round. The round was led by Forrestal Capital, a fund with specific experience...
XADAGO (safinamide) now available in the USA for Parkinson’s disease patients
XADAGO (safinamide) is now available as an add-on therapy for US patients with Parkinson’s disease currently taking levodopa/carbidopa and experiencing “off” episodes. It is not...
Transcranial stimulation and/or physical therapy improves walking speed in Parkinson’s disease
Non-invasive brain stimulation and physical therapy—alone or in combination—improve some measures of walking ability in patients with Parkinson’s disease, concludes a clinical trial in...
Parkinson’s disease patients first to be treated with Leksell Vantage Stereotactic...
The Leksell Vantage Stereotactic system (Elekta) is now in clinical use at three European centres. The first surgeries were performed on a patient with...
CE mark for Vercise Gevia deep brain stimulation system
CE mark has been granted for the Vercise Gevia deep brain stimulation (DBS) system (Boston Scientific), a rechargeable, magnetic resonance (MR) conditional device indicated...
SureTune3 deep brain stimulation software receives Health Canada licence
Medtronic has received a Health Canada licence for SureTune3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology are designed...
First patient enrolled in APPRISE clinical study for optimisation of Parkinson’s...
Global Kinetics Corporation (GKC) and the Parkinson’s Foundation have announced that the first of over 400 patients has been enrolled in the GKC APPRISE...
Blood test may help differentiate Parkinson’s from atypical Parkinsonism disorders
A blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson’s disease or...
Spinal cord stimulation leads to “significant improvement” in gait in Parkinson’s...
A recent study explores the safety and efficacy of spinal cord stimulation on gait disturbance in advanced Parkinson’s disease. The investigators found that spinal...
Infinity deep brain stimulation system approved in the USA
St Jude Medical has announced the United States Food and Drug Administration approval and first implant of the Infinity deep brain stimulation (DBS) system...
Study finds deep brain stimulation a cost-effective treatment method for Parkinson’s...
It has been established that deep brain stimulation is clinically superior to medical therapy for treating advanced Parkinson’s disease. Jan B Pietzsch (Department of...
